Maia Pharms Inc Company Profile

What is the competitive landscape for MAIA PHARMS INC, and what generic alternatives to MAIA PHARMS INC drugs are available?

MAIA PHARMS INC has nine approved drugs.

There are seven US patents protecting MAIA PHARMS INC drugs.

There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-two supplementary protection certificates in nine countries.

Summary for Maia Pharms Inc

International Patents:	4
US Patents:	7
Tradenames:	6
Ingredients:	6
NDAs:	9

Drugs and US Patents for Maia Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210315-001	Jul 30, 2019	AP	RX	No	No
Maia Pharms Inc	BORTEZOMIB	bortezomib	SOLUTION;INTRAVENOUS	215331-001	Jul 27, 2022		DISCN	Yes	No	11,679,119
Maia Pharms Inc	BORTEZOMIB	bortezomib	SOLUTION;INTRAVENOUS	215331-002	Jul 27, 2022		DISCN	Yes	No	11,679,119
Maia Pharms Inc	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	210048-001	Sep 11, 2019	AP	RX	No	No
Maia Pharms Inc	SODIUM PHENYLACETATE AND SODIUM BENZOATE	sodium benzoate; sodium phenylacetate	SOLUTION;INTRAVENOUS	208521-001	May 8, 2017	AP	RX	No	No
Maia Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	208749-001	Dec 21, 2018	AP	RX	No	No
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,903,993

Paragraph IV (Patent) Challenges for MAIA PHARMS INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	for Injection	200 mcg/vial		2015-05-01

International Patents for Maia Pharms Inc Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2023049346
European Patent Office	3672616
World Intellectual Property Organization (WIPO)	2019040904
Canada	3073944

Supplementary Protection Certificates for Maia Pharms Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1948158	1690020-1	Sweden		PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
1856135	CR 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
0788511	SPC/GB08/036	United Kingdom		PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
1666481	17C1031	France		PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324
0480717	SPC/GB98/025	United Kingdom		PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
2822954	1890030-8	Sweden		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
1259550	08C0052	France		PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Maia Pharms Inc